Tag: Oncotarget

Targeting the multifaceted BRAF in cancer: New directions

New Directions in Targeting the Multifaceted BRAF in Cancer

August 12, 2024

“Here we discuss the diverse forms of BRAF alterations found in human cancers and the strategies to inhibit them in patients harboring cancers of distinct origins.” BUFFALO, NY- August 12,… read more

Oncotarget

Oncotarget at SSP 46th Annual Meeting

May 13, 2024

Oncotarget is proud to participate at the Society for Scholarly Publishing (SSP) 46th Annual Meeting from May 29–31, 2024, in Boston, Massachusetts. BUFFALO, NY- May 13, 2024 – Impact Journals… read more

Figure 4: The effect of SARS-CoV-2 spike on cell growth and death.

Oncotarget

Transfected SARS-CoV-2 Spike DNA Suppresses Cancer Cell Response to Chemotherapy

May 6, 2024

“Our findings have implications for the natural history of prolonged or repeated SARS-CoV-2 infection as well as design of anti-COVID-19 vaccines that are administered repeatedly as booster shots.” BUFFALO, NY-… read more

Figure 7: B-cell depletion of BTA106 in cynomolgus monkeys.

Oncotarget

Novel Therapeutic Bispecific Antibodies for B-cell Lymphoma

April 16, 2024

“Our results indicate that IgM-dependent bispecific antibodies are potent therapeutic agents for B-cell malignancies.” BUFFALO, NY- April 16, 2024 – A new research paper was published in Oncotarget's Volume 15… read more

Figure 2: Effect of treatment with MIA-602 on the growth of Doxorubicin-resistant K-562 tumors xenographed into nude mice.

Oncotarget

Exploring the Role of MIA-602 in Overcoming Doxorubicin-resistance in Acute Myeloid Leukemia

April 10, 2024

“Our results reveal that MIA-602 may be a useful treatment for Doxorubicin-resistant AML [...]” BUFFALO, NY- April 10, 2024 – A new research paper was published in Oncotarget's Volume 15… read more

Figure 2: Preemptive combinations. (A) EGFR-Mutant-Driven NSCLC. See text. (B) METex14-Driven NSCLC. See text.

Oncotarget

“From Osimertinib to Preemptive Combinations” by Dr. Blagosklonny

March 19, 2024

“Here I will re-introduce the notion of preemptive combinations (PC) of targeted drugs.” BUFFALO, NY- March 19, 2024 – A new research perspective was published by Mikhail V. Blagosklonny M.D.,… read more

Oncotarget

BRCA1 and BRCA2 in a Cohort of Ovarian Cancer Patients From the Salento Peninsula

February 28, 2024

“Ovarian cancer (OC) is the third most prevalent type of gynecologic cancer affecting women after cervical and uterine cancer [1]. It is also considered the most fatal of all gynecological… read more

Oncotarget

The Double-Edge Sword of CRISPR Application for In Vivo Studies

November 28, 2023

“The Achilles’ heel of CRISPR application is the delivery of sgRNA/Cas9 to the desired tissues.” BUFFALO, NY- November 28, 2023 – A new editorial paper was published in Oncotarget's Volume… read more

Figure 1: Chromatin landscape of the glioma GWAS locus rs55705857 in the melanocyte lineage.

Oncotarget

Predicting the Molecular Functions of Regulatory Genetic Variants Associated With Cancer

November 20, 2023

“Effectively integrating these rich resources with GWAS results will continue to help prioritize causative inherited genetic variants and improve our molecular understanding of disease etiology [...]” BUFFALO, NY- November 20,… read more

Oncotarget

An Ancient Anti-cancer Mechanism: DISE

October 3, 2023

“DISE is effective against all cancers we tested.” BUFFALO, NY- October 3, 2023 – A new editorial paper was published in Oncotarget's Volume 14 on September 25, 2023, entitled, “DISE,… read more